EGFR and non-small cell lung carcinoma: Notably, CASK loss did not affect EGFR trafficking to early endosomes but delayed its transition to late endosomes in an ERK-dependent fashion, thereby reducing receptor degradation.<h4>Conclusions</h4>We identified CASK as a previously unrecognized driver of NSCLC growth and a potential prognostic biomarker.